Eagle Pharmaceutics Inc. EGRX announced Wednesday that it had won the Food and Drug Administration’s Qualified Infectious disease Product (QDIP), and Fast-Track designation for CAL02 – a treatment to treat severe community-acquired pneumonia (SCABP), as an addition therapy to standard care. If the product is approved, the former designation will give the company an additional 8-10 years of regulatory exclusivity. Eagle believes CAL02 to be a new chemical entity that would give it five years of exclusivity in marketing. This underscores the unmet medical needs in treating SCABP – a global disease that…